Fig. 6: Cannabinoids reduce anaphylaxis in peanut sensitised BALB/c mice.

a Scheme of the epicutaneous sensitisation protocol; i.p., intraperitoneally. b Clinical signs observed after challenge with crude peanut extract (CPE, 2.5 g/mouse) or CPE plus WIN55212-2 (WIN, 20 µg/mouse). c Left, changes in body temperature 40 min after challenge. *Naïve vs CPE-Sensitised/CPE Challenge, #CPE-Sensitised/CPE Challenge vs CPE-Sensitised/CPE + WIN55212-2 Challenge, + Naïve vs CPE-Sensitised/CPE + WIN55212-2 Challenge. Right, area under the curve (temperature vs time) of the indicated conditions. d Hemoconcentration 40 min after challenge. e Left, one representative example of spleen size and right, spleen weight 72 h after challenge. f Left, percentage of spleen FOXP3⁺ Tregs in the indicated conditions. Right, Flow cytometry representative dot plots of generated splenic FOXP3⁺ Tregs. g Cytokine production and (h) cytokine ratios by splenocytes from the indicated mice, stimulated in vitro with CPE (250 µg/mL) for 4 days. i Increment of FOXP3⁺ Tregs generation after in vitro CPE stimulation for 4 days relative to unstimulated condition. j Negative correlation of increased Tregs with IL-5 levels produced by CPE-stimulated splenocytes. Values are the mean ± SEM. n = 5–10 of two independent experiments. Statistical significance was determined using One-way Anova and Spearman test (j): *P < 0.05, **P < 0.01 and ***P < 0.001.